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ABSTRACT 
Triglycerides are the main form of energy in the tissues and liver, along with the adipose 
tissue, is the main organ of triglyceride metabolism and storage in the lipid-droplet 
organelles. A number of proteins are involved in the regulation of the triglyceride metabolism 
in human liver, however their specific role is still not thoroughly known. The aim of this 
thesis is to evaluate the functional role of three proteins in triglyceride regulation in an 
experimental model of human liver.  
In Paper I we identified the gene Transmembrane 6 superfamily member 2 (TM6SF2) as the 
putative cause for the association between the 19p12 locus with plasma triglyceride levels 
and non-alcoholic fatty liver disease, by employing expression studies and expression 
quantitative trait locus analysis in 206 human liver samples. TM6SF2 encodes a protein of 
351 amino acids localized in the Endoplasmic reticulum (ER) and the ER-Golgi intermediate 
compartment, as investigated in human hepatoma cells. Functional studies showed that 
TM6SF2 siRNA inhibition led to reduced secretion of triglyceride-rich lipoproteins (TRLs) 
and increased cellular triglyceride concentration and number of lipid-droplets, however the 
putative pathophysiological mechanism of these observations is still unclear. 
In Paper II we investigated the physiological functions of Patatin-like phospholipase domain 
containing proteins 2, 3 and 4 (PNPLA2, PNPLA3 and PNPLA4), as potential triglyceride 
hydrolases in Huh7 and HepG2 human hepatomas. We found that siRNA inhibition of 
PNPLA3 or PNPLA4 is not associated with changes in triglyceride hydrolysis, TRL secretion 
or cellular triglyceride accumulation. However, PNPLA2 siRNA inhibition reduced 
intracellular triglyceride hydrolysis and decreased TRL secretion, both in the absence or 
presence of oleate-containing medium or of the PNPLA2 inhibitor Atglistatin. In contrast, we 
found no effects of PNPLA2 inhibition on lipid-droplet homeostasis. Visualization analysis 
with confocal microscopy found significant co-localization of PNPLA2 with the ER, but no 
clear evidence for PNPLA2 localization around the lipid-droplets. This data indicates that 
PNPLA2 hydrolyses a triglyceride compartment comprising of very small lipid-droplets that 
are involved in the regulation of TRL secretion, but are not detectable by confocal 
microscopy. 
In Paper III we studied the likely role of Abhydrolase domain-containing 5 (ABHD5) as the 
co-activator of PNPLA2 in the regulation of hepatic triglyceride metabolism. We employed 
siRNA inhibition techniques in Huh7 hepatoma cells and showed that ABHD5 siRNA 
inhibition reduced triglyceride hydrolysis and decreased TRL secretion while there was no 
effect on cellular triglyceride content. These results are similar to the effects of PNPLA2 
siRNA inhibition on triglyceride metabolism as examined in Paper II. We also found no 
additive effects of combined ABHD5-PNPLA2 siRNA inhibition in hepatic triglyceride 
metabolism. We employed confocal microscopy analysis and observed localization of 
ABHD5 in the ER, but not in Golgi or around the lipid-droplets, while a significant co-
localization of ABHD5 and PNPLA2 was observed. These observations suggest that ABHD5 
is a co-activator of PNPLA2 with no separate triglyceride hydrolysis activity in human 
hepatocytes. 
Overall, this Thesis identifies TM6SF2 as a membrane protein regulating the TRL secretion 
in Huh7 and HepG2 hepatoma cells. It also demonstrates the role of triglyceride hydrolysis in 
the regulation of TRL secretion where PNPLA2 is the main triglyceride hydrolase activated 
by ABHD5. Finally, it suggests the existence of very small lipid-droplets containing the 
substrate compartment of the PNPLA2- and ABHD5-mediated triglyceride hydrolysis. 
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1 INTRODUCTION 
 
1.1 TRIGLYCERIDES AND LIVER 
Triglyceride is the most concentrated energy form found in biological tissues 1. It is an ester 
consisting of three fatty acids and one glycerol backbone. Fatty acids are the essential 
substrates for membrane lipids and lipids involved in cellular signaling. However, high 
concentrations of non-esterified fatty acids (NEFA) distort the integrity of cellular 
membranes, alter the intracellular pH balance and evoke the production of harmful bioactive 
lipids. This leads to lipotoxicity, a condition characterized by cellular stress, organelle 
dysfunction and cell death. In contrast, triglycerides show low biological toxicity and are well 
tolerated in the tissues and cells. Thus, they provide a “safe” and efficient form of fatty acid 
storage and transportation via the process of triglyceride synthesis and triglyceride hydrolysis. 
Triglycerides are thus part of a well-regulated mechanism ensuring the esterification of fatty 
acids to triglycerides and cholesterol esters and providing a balance between the fatty-acid 
uptake, storage, utilization and secretion in the tissues 2. 
Triglycerides are synthesized in most tissues by the acyl CoA:diacylglycerol acyltransferase 
(DGAT) 1 and 2 enzymes, as reviewed in 3, however they are stored only in few tissues; 
skeletal muscle and the heart can store tiny amounts of triglycerides while the adipose tissue 
and the liver are the most important storage pools of neutral lipids, storing them in specialized 
intracellular organelles called lipid-droplets 4. However, other cells also store lipids in lipid-
droplets, including enterocytes, macrophages and adrenocortical cells.  
The liver is the central organ responsible for lipid homeostasis. Hepatocytes are the major 
cell-type responsible for the triglyceride metabolism and storage in the lipid droplets. 
Additional cell types within the liver include stellate cells, Kupffer cells, biliary epithelial 
cells and liver sinusoidal endothelial cells, all of which have specialized and unique 
physiological functions 5. 
 
 
 
 
 
 
 
 2 
1.2 INTRACELLULAR LIPID METABOLISM 
 
In a number of excellent reviews, lipid-droplets 
are described as  a necessary cell compartment 
of lipid reservoirs for cell membrane 
components and metabolic energy 6–10. Lipid-
droplets are mostly formed in the ER and they 
have a nonpolar, neutral lipid core comprising of 
triglycerides, cholesterol esters and/or retinol 
esters (Figure 1) 11. The cytosolic triglyceride 
pools derive from esterification of the following 
sources: 1. fatty acids originating from de novo 
lipogenesis, 2. exogenous-derived NEFA 
circulating in plasma and 3. fatty acids deriving 
from the uptake and hydrolysis of lipoprotein 
remnants 12. The lipid-droplet core is surrounded 
by a phospholipid surface monolayer of 
phosphatidylcholine with lesser amounts of 
phosphatidylethanolamine, phosphatidylinositol, lyso-phosphatidylcholine, and lyso-
phosphatidylethanolamine.13 There are two main classes of lipid-droplet-associated proteins: 
proteins stably associated with membranes that partition between lipid-droplets and the ER 
(class I proteins) and proteins recruited directly from the cytosol to the lipid droplet surface 
(class II proteins) 11. Depletion of proteins that change the phospholipid content dramatically 
changes lipid-droplet morphology 14–17. Some proteins bind to the lipid-droplet surfaces and 
regulate their size and number. These proteins include, among others, the Perilipin2 (PLIN2) 
protein which is highly expressed in liver 18,19. 
Imbalances in the regulatory mechanisms of lipid homeostasis in human liver may lead to 
steatosis, the unphysiologically high concentration of triglyceride in the liver cells (usually 
defined as hepatic triglyceride content > 5%). These imbalances include increased substrate 
availability for triglyceride synthesis and lipid-droplet formation as well as impaired 
triglyceride mobilization due to disturbances in lipid-droplet hydrolysis, fatty-acid oxidation 
or TRL assembly and secretion 20. 
Steatosis is considered as the first stage of nonalcoholic fatty liver disease (NAFLD), a 
spectrum of liver disease in the absence of high alcohol consumption. The disease spectrum 
comprises of, initially, hepatic steatosis, developing through hepatic steatohepatitis (presence 
of liver fat in combination with liver inflammation and degeneration), resulting to fibrosis 
and ultimately to cirrhosis or in some cases to hepatocellular carcinoma 21. The prevalence of 
nonalcoholic fatty liver disease is increasing worldwide representing a serious public health 
problem and is strongly associated with type 2 diabetes mellitus and cardiovascular 
Figure 1. Schematic representation of a lipid-
droplet illustrating their complexity and overall 
structure. Reproduced with permission from 
Olzmann & Carvalho 11. 
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disease. Weight loss is currently the only effective treatment option for NAFLD with no 
pharmaceutical treatments yet approved 21,22. 
The main hallmark feature of hepatic steatosis is the triglyceride accumulation in the lipid-
droplets and appears in two morphological variations: in macrovesicular steatosis large lipid 
droplets are present in the cytoplasm and displace the nucleus whereas in microvesicular 
steatosis a high number of smaller lipid-droplets accumulates within the hepatic cytoplasm 
with the nucleus remaining intact 23. Overall, it becomes clear that impairments in the lipid-
droplet homeostasis including biogenesis and triglyceride mobilization may lead to hepatic 
steatosis and cardiovascular disease. 
 
1.2.1 Biogenesis of lipid-droplets 
The mechanism of lipid-droplet biogenesis is still poorly understood despite the recent 
discoveries and it comprises of a number of different steps, as shown in Figure 2 and 
reviewed in 11,24. 
 
 
Step 1. Triglyceride synthesis within the ER. This is a result of esterification of activated fatty 
acids into triglycerides and cholesterol esters. Triglycerides are synthesized mainly by the 
diacylglycerol acyltransferases (DGAT1 and DGAT2). These enzymes are localized 
primarily in the ER. It has been suggested that, despite the fact that DGAT1 and DGAT2 can 
compensate for each other for triglyceride synthesis, these triglyceride synthesis enzymes 
have different roles at least in primary hepatocytes; the triglyceride which is synthesized by 
DGAT1 is preferentially channeled to oxidation, whereas DGAT2 synthesizes triglyceride 
destined for very low-density lipoprotein assembly 25. The synthesized triglyceride 
accumulates in an initial lens-like shape within the ER membrane bilayer. 
Figure 2. Schematic representation of lipid droplet biogenesis. Reproduced with permission from  
Walther TC et al 24. 
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Step 2. Formation of an oil lens. Neutral lipid deposition occurs between the two leaflets of 
the ER bilayer 26. Once the concentration of neutral lipids exceeds a critical threshold, lipid 
(oil) lenses begin to shape and grow. No proteins have been identified to play a direct role in 
lens formation. 
Step 3. Budding of lipid-droplets. At some point, the growing structure is predicted to bud off 
the ER, forming an “initial” lipid-droplet (iLD). According to this model, the lipid-droplet 
budding occurs spontaneously when sufficient triglycerol has influxed, in combination with 
lower tension and elastic moduli on the lipid-droplet surface 27. Seipin, an ER membrane 
protein, has been shown to play a major role in correct lipid-droplet budding by allowing 
more triglycerides to be added into the newly formed lipid-droplets15 28. After budding, lipid-
droplets grow and expand. This is achieved in two different ways; first, by fusion of one or 
more nascent lipid-droplets via ER membrane bridges, which allows the transfer of 
triglyceride and formation of one bigger lipid-droplet. Second, through re-localization of 
several enzymes from the ER to the lipid-droplet surface which enables triglyceride synthesis 
directly on the lipid-droplet surface, thus making the newly formed triglyceride to accumulate 
in the lipid-droplet core 29.  
1.2.2 Lipid-droplet hydrolysis 
Fatty acids are mobilized from the lipid-droplet core with the purpose of providing the cell 
with substrate for its metabolic needs. This is mainly done with lipolysis (triglyceride 
hydrolysis) which has been extensively studied and clarified in the human adipose tissue 
(Figure 3). In adipose tissue, lipid-droplet hydrolysis generates fatty acids for secretion by 
adipocytes. In the liver, lipid-droplet hydrolysis provides fatty acids for β-oxidation, cellular 
signaling, phospholipid precursors for cell membranes as well as the necessary substrates for 
the assembly and secretion of lipoproteins 30.  
 
 
 
 
 
 
 
 
 
Figure 3. Overview of triglyceride hydrolysis 
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The first step in the triglyceride hydrolysis in adipocytes is catalyzed by PNPLA2, also 
known as Adipose triglyceride lipase (ATGL) which was identified as a protein-encoding 
gene with abundant triglyceride lipase activity 31 and established as the triglyceride lipase in 
murine and human adipose tissue 32. PNPLA2 encodes a 504–amino acid protein with 86% 
identity to the mouse enzyme. PNPLA2 is also expressed in the cardiac muscle and liver, 
however at lower levels compared to the adipose tissue. Previous studies have shown that 
knockdown or inactivation of PNPLA2 in murine liver leads to hepatic steatosis in mice and 
decreased triglyceride hydrolysis activity in primary murine hepatocyte cultures whereas 
overexpression in mouse liver ameliorates hepatic steatosis. This data provides support for a 
role of PNPLA2 in hepatic triglyceride hydrolysis and metabolism in rodents, however there 
are no studies elucidating the role of PNPLA2 in human hepatocytes 30. PNPLA3 and 
PNPLA4, two additional members of the PNPLA2 gene-family expressed in human 
hepatocytes, have been shown to have in vitro triglyceride hydrolase activity. However, the 
functional significance of PNPLA3 and PNPLA4 in human liver triglyceride metabolism has 
not been established, as reviewed in 33. 
The next steps of triglyceride lipolysis involve the cleavage of diglycerol into monoglycerol 
and the subsequent cleavage of monoglycerol to glycerol and fatty acids. These processes are 
catalyzed in adipose tissue by hormone-sensitive lipase and monoglyceride lipase 
respectively, as reviewed in 34 . These enzymes have been well-characterized in the adipose 
tissue but it has been suggested that other triglyceride hydrolases are involved in the human 
liver as well.  
In addition to the previous enzymes, the process of triglyceride hydrolysis is controlled by a 
number of proteins and co-factors. Abhydrolase domain containing-5 protein (ABHD5), also 
known as CGI-58, is a member of an esterase/thioesterase/lipase gene family. It has been 
implicated in having a role in triglyceride hydrolysis, as well as in TRL assembly and 
secretion, via activation of PNPLA2 as investigated in adipocytes and myocytes 35,36. Liver-
specific inhibition of ABHD5 in mice has shown to induce hepatic steatosis 37,38 and 
reduction in triglyceride hydrolase activity and TRL secretion 37. Similarly, rat hepatoma cells 
deficient in ABHD5 exhibit accumulation of cellular triglyceride in combination with a 
decrease in triglyceride and APOB-VLDL secretion due to decreased triglyceride hydrolysis 
39,40. Despite the role as a co-activator of PNPLA2, it has been recently proposed that ABHD5 
may exhibit lipolytic activities at a PNPLA2-independent manner 41. Nevertheless, little is 
known about the function of ABHD5 in human liver and whether it possesses lipolytic 
activities independently of PNPLA2. 
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1.2.3 TRL assembly and secretion 
The assembly and secretion of TRLs from the liver has been analyzed for more than 50 years 
and the results of these studies have been summarized in a number of excellent review 
articles 42–46. An important breakthrough was the identification of two APOB proteins, 
APOB100 and APOB48, the essential structural components of TRLs secreted by the liver 
and intestine, respectively 47. The subsequent cloning of APOB provided the tools to study in 
more detail the biosynthesis and intracellular transport of APOB in hepatocytes using, for 
example, pulse-chase methods in different liver-cell models. These studies demonstrated that 
the hepatic TRL assembly process starts with the lipidation of the growing APOB100 protein 
in the lumen of the ER. This lipidation process continues until the precursor TRL has 
acquired sufficient quantities of triglycerides to permit APOB to fold correctly on the particle. 
Further additions of triglyceride occur in the transition of the lipoprotein particle from the ER 
to the Golgi. The mature TRL is subsequently secreted by the hepatocyte via an as yet ill-
defined transport process. 
There is evidence that APOB100 is constitutionally expressed in the liver, indicating that 
transcriptional regulation of APOB is of minor importance in the regulation of TRL secretion. 
It was found that the availability of lipids, in particular triglycerides, is a crucial factor in the 
regulation of TRL assembly and secretion 48. It was shown that the lack of triglycerides leads 
to the retention of precursor TRLs in the secretory pathway and ultimately induces a 
proteosomal degradation process of precursor TRLs. It was therefore proposed that post-
transcriptional degradation of APOB constitutes an important mechanism for the regulation 
of TRL synthesis and secretion. Surprisingly, the regulation of the supply of triglycerides for 
TRL synthesis has not been studied in detail and little is known regarding the involvement of 
specific proteins/enzymes in this process.  
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1.3 LIPOPROTEIN METABOLISM 
Triglycerides and cholesterol esters are crucial sources of energy and building-blocks of 
membranes. Since these molecules are insoluble in water, they are transported to different 
organs through the circulation in association with apolipoproteins, forming particles called 
“lipoproteins”. Thus, the lipoproteins play a pivotal role in the transport of dietary lipids from 
the intestine and the liver to the peripheral tissues as well as the reverse cholesterol transport.  
1.3.1 Classes of lipoproteins 
There are different types of lipoproteins but all of them consist of specific apolipoproteins, 
nonesterified cholesterol and phospholipids spherically surrounding a neutral-lipid core that 
contains triglycerides and cholesterol esters. The surface apolipoproteins can be APOA-I, 
APOA-II, APOA-IV, APOA-V, APOB48, APOB100, APOC1, APOCII, APOE and APO(a). 
The plasma lipoproteins are divided into seven classes which are shown in Figure 4 49,50. 
 
  
 
In summary, the lipoprotein division is dependent upon their size (density), lipid composition 
and type of surface apolipoprotein. The different lipoproteins, given by their name and their 
size from the smallest to the largest scale, are the following 51; chylomicrons (75-1200 nm), 
chylomicrons remnants (30-80 nm), very-low density lipoproteins (VLDL) (30-80 nm), 
intermediate-density lipoproteins (IDL) (25-35 nm), low-density lipoproteins (LDL) (18-35 
nm), high-density lipoproteins (HDL) (5-12 nm) and lipoprotein (a) (Lp(a)) (~30 nm). 
Figure 4. Classes of lipoproteins. Reproduced with permission from  
Feingold & Grunfeld 49. 
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1.3.2 Exogenous lipoprotein pathway 
After a meal, dietary triglycerides and cholesterol esters are hydrolyzed in the gastrointestinal 
tract by intestinal and pancreatic lipases. The produced monoglycerols, fatty acids and 
cholesterol are absorbed by the enterocytes. The enterocytes form new triglyceride and 
cholesterol esters which are packaged in chylomicrons in the intestinal ER. Every 
chylomicron particle contains also one APOB48 molecule, which is a truncated,  post-
translationally cleaved form of APOB100 produced by the intestine which does not bind 
LDL-receptors 43. The chylomicrons are secreted into the lymph and, via the thoracic duct 
and systemic circulation, are delivered to the adipose tissue, the muscle and other tissues. 
Chylomicrons become the substrate of lipoprotein lipase (LPL), a highly expressed enzyme 
on the capillary endothelium 52. This results in a significant decrease in the chylomicron size 
and formation of chylomicron remnants which, being poor in triglyceride but enriched in 
cholesterol esters, acquire APOE. Subsequently, the remnant particles are entirely taken up 
by the liver due to the binding of the APOE to the hepatocyte LDL-receptor via endocytosis, 
leading to their clearance from the circulation. Thus, the exogenous lipoprotein pathway 
provides an efficient delivery of dietary lipids to the periphery tissues while the produced 
cholesterol is transferred to the liver for utilization to VLDL or bile acids formation 49,50,53,54. 
1.3.3 Endogenous lipoprotein pathway 
A number of triglycerides and cholesterol esters, which are synthesized and stored in the 
liver, are subsequently used for the formation and secretion of the VLDL lipoproteins. The 
hepatocytes synthesize APOB100 and the Microsomal triglyceride transfer protein transfers 
the lipids from the cytosolic part of the ER to the lumen where the triglyceride-rich VLDL 
lipoprotein is generated 55.The VLDL is secreted via the Golgi apparatus 56 and transported to 
the peripheral tissues via the circulation where it gets hydrolyzed by the LPL in a similar way 
to the chylomicrons 52. The removal of triglycerides from the VLDL particles gradually leads 
to the transformation of VLDL to APOE- and cholesterol ester-enriched IDL. A fraction of 
the IDL lipoproteins are removed from the circulation via binding of their APOE molecule to 
the liver LDL-receptor. The IDL that remains in the circulation is hydrolyzed by LPL, 
generating LDL. The LDL particle consists mostly of cholesterol ester and APOB100 and is 
taken up by the hepatocytes via LDL-receptor mediated endocytosis. The levels of LDL-
receptors expressed on the hepatocyte surface are regulated by the cholesterol content of the 
cell. A decrease in the number or activity of the LDL-receptors leads to decreased LDL 
clearance, and thus to a higher LDL concentration in the circulation 49. 
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1.3.4 HDL metabolism and reverse cholesterol transport 
HDL particles are characterized by high density and small size. Their surface coat is 
composed of apolipoproteins, non-esterified cholesterol and phospholipids while the core 
primarily contains cholesterol esters. However, the HDL compositions change and evolve as 
the HDL circulate in the plasma 49. The main HDL structural protein (APOA1) is synthesized 
and secreted predominantly by the liver and the intestine and becomes lipidated with 
cholesterol and phospholipids; the primary lipids source is mostly identified from hepatocytes 
and enterocytes, as well as extrahepatic tissues such as myocytes and adipocytes. However, it 
has been observed that HDL can obtain cholesterol and phospholipids from chylomicrons and 
VLDL during their hydrolysis by the LPL. The cholesterol-rich HDL lipoprotein is mainly 
transferred to the liver where only the cholesterol compound is absorbed by the hepatocytes 
without internalization of the whole HDL particle. The cholesterol-poor HLD particle is 
subsequently released back into the circulation. Under some unknown conditions, Cholesterol 
ester transfer protein can catalyze cholesterol transfer from the HDL molecule to APOB 
containing particles resulting in triglyceride-rich HDL 57. In conclusion, the reverse 
cholesterol transport plays a pivotal role in the cholesterol homeostasis and in protecting from 
the development of atherosclerosis 26,49,53,54,58–62 . 
 
 
 
 
 
 
Figure 5. Endogenous and exogenous lipoprotein metabolism 135. 
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1.4 TRIGLYCERIDES AND CARDIOVASCULAR DISEASE 
Cardiovascular disease (CVD) is the leading cause of morbidity, mortality and disability in 
industrialized countries and the prevalence of these diseases is increasing rapidly in 
developing countries, with approx. 17,5 millions of deaths worldwide in 2012 63. Coronary 
heart disease (CHD) is the most common type of CVD caused by atherosclerosis. 
Atherosclerosis is a chronic disease characterized by artery-wall thickening as a result of 
invasion and accumulation of cholesterol enriched-differentiated macrophages (foam cells) 
and proliferation of intimal-smooth-muscle cell. The created fibrofatty plaque disturbs the 
blood flow causing occlusive thrombosis with high possibility for tissue infarction 64. Several 
excellent reviews have reported a range of atherogenic risk factors that give rise to increased 
CVD risks including male gender, age, ethnicity, socio-economic status, family history of 
CVD, smoking, alcohol consumption, type 1 and 2 diabetes mellitus, hypertension, obesity 
and disturbances of the plasma lipid profile 65. 
Atherogenic dyslipidemia has been shown in population studies to be significantly associated 
with higher CVD risk 66 67 and consists of altered lipid profile in the blood circulation which 
involves the following conditions: increased LDL- and triglyceride concentration and 
decreased HDL concentration 68.  A major characteristic of atherogenic dyslipidemia is that it 
is found in patients with obesity, the metabolic syndrome, insulin resistance, and type 2 
diabetes mellitus 69. 
An important component of atherogenic dyslipidemia is the increased plasma triglyceride 
concentration. The secretion of large triglyceride-rich VLDL lipoproteins leads to reduced 
clearance of chylomicrons and chylomicron remnants due to competition for binding and 
triglyceride hydrolysis by lipoprotein lipase. The cholesterol-rich lipoprotein remnants are 
highly atherogenic, thus triggering the foam cell formation and substantially contributing to 
the cholesterol accumulation in the arterial wall, as reviewed in 70,71. Additionally, the high 
triglyceride content of VLDL lipoproteins leads to triglyceride enrichment of LDL and HDL. 
This results in the accumulation of small, dense LDL and triglyceride-enriched HDL particles 
that are highly atherogenic. The LDL particles are susceptible to oxidation when present in 
the vessel wall, leading to the formation of the atherosclerotic plaque. Triglyceride-enriched 
HDL becomes substrate for lipolysis by hepatic lipase, leading to HDL catabolism and 
reduced reverse cholesterol transport. For this, there has been shown a positive association 
between the progression of CVD and the concentrations of triglyceride-rich lipoprotein 
remnants 72. 
Triglyceride levels are highly dependent on genetic factors whereas several environmental 
factors, such as alcohol intake and diabetes, may increase hypertriglyceridemia. As reviewed 
in 73, the epidemiological associations between plasma triglyceride levels and CHD risk is not 
as strong as with LDL levels. However, genome-wide association (GWA) studies have lately 
provided genetic evidence that TRLs, as assessed by plasma triglycerides, represent a 
“casual” risk factor because of the linkage between single nucleotide polymorphisms (SNPs) 
  11 
in genes modulating plasma triglyceride levels and CHD risk 73. These studies have 
stimulated the interest in targeting triglyceride metabolism for therapeutic purpose. 
Several GWA studies have identified a locus on chromosome 19p12, also-called NCAN 
locus, in association with plasma triglyceride and LDL levels. 19p12 locus was found to be 
associated with hepatic triglyceride content and non-alcoholic fatty liver disease 74,75. 
Nevertheless, 19p12 locus consists of at least 19 different genes with the gene responsible for 
the reported associations not been identified at the beginning of this Thesis. The overall aim 
of the studies presented in this Thesis is to evaluate the functional roles of three proteins 
involved in hepatic triglyceride metabolism in the regulation of the TRL synthesis and 
secretion.            
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2 HYPOTHESIS AND AIMS 
 
2.1 GENERAL HYPOTHESIS 
The liver plays a major role in the regulation of TRL metabolism. A large number of proteins 
are involved in the control of different aspects of the hepatic triglyceride homeostasis, 
including triglyceride-synthesis, -storage, -hydrolysis and TRL secretion, but the specific 
roles of these proteins have not been analyzed in detail.  The aim of this thesis is to 
functionally characterize three proteins (TM6SF2, PNPLA2 and ABHD5) that influence 
triglyceride metabolism in the human liver. 
2.2 SPECIFIC AIMS 
Paper I. 
Hypothesis. GWA studies have identified a genetic locus (19p12) associated with both 
variations in the plasma triglyceride concentration and risk for NAFLD, but the gene/protein 
responsible for these relationships has not been uncovered. We hypothesized that this 
unknown protein plays a role in hepatic triglyceride metabolism, specifically in relation to 
TRL secretion and lipid-droplet metabolism.  
Aim. To identify the gene in the 19p12 locus associated with plasma triglyceride 
concentrations and NAFLD and to investigate the phenotype of the protein in relationship 
with its hepatic expression, sub-cellular localization and impact on TRL secretion and lipid-
droplet metabolism in human hepatoma cells. 
 
Paper II. 
Hypothesis. Three members of the PNPLA protein family, PNPLA2, PNPLA3 and PNPLA4 
are expressed in human liver cells and are able to hydrolyze triglycerides as analyzed using in 
vitro systems. However, the physiological roles of these PNPLA proteins in hepatic 
triglyceride metabolism are largely unknown.  
Aim. To investigate the physiological roles of PNPLA2, PNPLA3 and PNPLA4 proteins in 
hepatic triglyceride metabolism by studying the effects of gene-specific siRNA inhibition of 
these proteins on TRL-secretion and lipid-droplet metabolism in human hepatoma cells.  
 
Paper III. 
Hypothesis. ABHD5 is a co-activator of PNPLA2 in adipocytes, but the physiological role of 
ABHD5 in human hepatocytes has not been established. Moreover, there is evidence that 
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ABHD5 may exhibit a physiological function in hepatic triglyceride metabolism that is 
independent from PNPLA2.  
Aim. To study the functional role of ABHD5 in hepatic triglyceride metabolism using gene-
specific siRNA inhibition and to evaluate the relationship between ABHD5 and PNPLA2 
with regard to TRL-secretion and lipid-droplet metabolism in human hepatoma Huh7 cells. 
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3 EXPERIMENTAL PROCEDURES 
 
3.1 HUMAN COHORTS 
For Paper I of this thesis, the human cohort derived from the Advanced Study of Aortic 
Pathology (ASAP) was used. This cohort is comprised of liver biopsies obtained from 
patients undergoing aortic valve surgery as described by 76. All protocols were approved by 
the ethics committee of the Karolinska Institutet and informed consent was obtained from all 
participants according to the Helsinki Declaration. Gene expression of the liver samples was 
analyzed using the Affymetrix GeneChip Human exon 1.0 ST microarray.  
 
3.2 CELL CULTURES 
Human immortalized liver-derived cell lines HepG2 and Huh7 were used for the functional 
studies in all the papers, purchased from the American Type Culture Collection (HB- 8065) 
and the Health Science Research Resources Bank (cell no. JCRB0403; Osaka, Japan) 
respectively. Huh7 is a well-established and differentiated hepatocyte cell-line originally 
obtained from the liver of a 57-year-old male with a well-differentiated hepatocellular 
carcinoma in 1982 77. As a verification of our results, we repeated most of our experiments in 
another hepatocellular carcinoma cell line, HepG2, which has also been widely used in 
studies as a model of human triglyceride metabolism 78.  
 
3.3 SMALL INTERFERING RNA (SIRNA) 
Gene inhibition allows the functional study of a particular gene/protein using in vitro or in 
vivo models. This can be achieved thanks to RNA interference (RNAi), a mechanism which 
induces gene silencing by targeting complementary mRNA for degradation with double-
stranded RNA (dsRNA) as reviewed in 79. The experimental protocol involves transfection 
with either synthetic small interfering RNA (siRNA) probes or with plasmids coding for 
short-hairpin shRNA molecules that resemble intermediates of the microRNA pathway and 
become activated intracellularly 80. In all our studies we used siRNA probes, obtained from a 
commercial supplier (Ambion), consisting of 20–30 nucleotides to reduce the expression of 
the selected target-genes. 
siRNA transfection requires “vehicles” which will deliver the siRNA to the appropriate site 
of action inside the cell. The delivery of such molecules is either accomplished by 
transfection using cationic liposomes, electroporation or by viral mediated delivery. In order 
to avoid the cytotoxicity caused by electroporation or the changes in the cell-host genome 
caused by viral-mediated techniques, the delivery method of our experimental approach was 
lipofection. In this procedure, cationic lipid-based particles interact electrostatically with the 
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siRNA and they form coated vesicles, the “lipoplexes”, with the nucleic acid in their core. 
The lipoplexes bind to the cell membrane and release their content in the cytoplasm. When 
siRNAs enter the cell, they bind to a multiprotein component complex known as RISC (RNA 
induced silencing complex) which becomes aligned on the target mRNA, thus leading to 
mRNA cleavage 81,82. 
 
3.4 RNA EXTRACTION AND SYNTHESIS OF CDNA 
RNA was extracted from the cells using E.Z.N.A. Total RNA Kit 1 (Omega Bio-tek), 
followed by quantification of the RNA concentration by Nanodrop1000 spectrophotometer 
(Thermo Fisher Scientific). cDNA was synthesized with a High-Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher Scientific) and PCR amplification. 
 
3.5 GENE EXPRESSION ANALYSIS 
We used Taqman primer probes and AB7500 sequence detection system (Applied 
Biosystems) to analyze the relative mRNA expression of selected genes. The Ct (threshold 
cycle number) values were obtained to assess the relative gene expression using the 
comparative ΔΔCT method and subsequently adjusting for the endogenous control RPLP0. 
The results were verified using the relative standard curve method according to the Applied 
Biosystems guidelines. 
 
3.6 IMMUNOBLOT ANALYSIS 
Immunoblotting was performed in order to validate the efficacy of siRNA transfection and to 
evaluate the level of protein reduction of the gene-targets in our studies. Proteins were 
extracted using RIPA buffer and immunoblots were performed as described in detail in every 
manuscript. The antibodies that were used are listed in the respective manuscript and were 
validated in previous studies. The visualization of the blots was performed by using a LAS-
1000 Imager (Fujifilm) while the intensities of the protein bands were measured by ImageJ 
software. Beta-actin was used as an endogenous control for normalization. 
 
3.7 CELL STAINING 
The subcellular localization of a protein of interest can be analyzed using fluorescent proteins 
available for microscopy with fluorescent- and confocal-microscopes. The protein of interest 
is cloned into a vector (plasmid) encoding a fluorescent tag. The cells are transfected with the 
vector and the fluorescent protein fusion is expressed within the target cell, thus making it 
possible to track the protein of interest. In Paper I we purchased from OriGene full-length 
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human probes for TM6SF2 and CALR proteins which were GFP-tagged or FP635- tagged in 
their C-terminal. The details of the plasmids, cellular transfection and the lipid-delivery can 
be found in the Material and Methods section of Paper I. 
The protein visualization with the plasmid transfection method has a number of 
disadvantages, including the possibility that the fused protein oligomerizes, becomes charged 
or changes its actual molecular size. It is thus possible that overexpression of a large or 
charged protein-construct can change the subcellular localization of the protein of interest 83. 
In addition, it is conceivable that protein overexpression generates an ‘overload’ of intra-
cellular protein, leading to the accumulation of the tagged protein at non-physiological sites. 
In order to deal with these problems, we visualized the proteins of interest in Papers II and III 
using fluorescently-labelled monoclonal antibodies. The use of monoclonal antibodies offers 
the advantage of high specificity against their protein-target as compared to polyclonal 
antibodies. However, minor changes in the structure of the antigen epitope due to the cell 
fixation or processing can affect the function of the monoclonal antibodies 84. Thus, for every 
study the appropriate monoclonal antibody as well as the cell-fixation method was selected 
with care.  
For visualization of the lipid droplets we used either Bodipy 493/503 or HCS LipidTox Red 
purchased from Life Technologies and Invitrogen, respectively. Both fluorochromes stain the 
lipid droplets in the cells thanks to their lipophilic nature and their specificity with neutral 
lipids 85,86. DAPI (4′, 6-diamidino-2-phenylindole), supplied by Vector Laboratories, was 
used for the staining of the cell nucleus. The protocols for cell fixation, permeabilization and 
staining with fluorescent dyes or antibodies are described in detail in Paper II and Paper III. 
 
3.8 CONFOCAL MICROSCOPY 
For visualization of the fluorescence-labelling we used a Leica SP5 inverted confocal 
microscope equipped with a 63×1.4 NA oil lens (Leica Microsystems). We obtained image z-
stacks consisting of multiple optical slices taken at 0.2-0.5 µm intervals. The details of the 
confocal microscopy as well as the analysis of the images can be found in the Materials and 
Methods section of every Paper. 
 
3.9 C14-LABELLING  
Fatty acids and glycerol are the “building blocks” for the hepatic triglyceride synthesis and 
predominantly derive as from triglyceride hydrolysis by adipose tissue 87. The process of the 
triglyceride metabolism in the hepatoma cell, from fatty acid esterification to the triglyceride 
secretion, can be traced by using triglyceride precursors labelled with radioisotopes. The use 
of stable isotope-labeled tracers allows for the quantitative evaluation of major pathways of 
the fatty acid and triglyceride metabolism in vivo. 
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In all our Papers, we analyzed triglyceride secretion by incubation of the hepatoma cells with 
C14-labelled glycerol. This semi-quantifying method allowed us to trace the C14-labelled 
triglyceride that was synthesized and to measure the secreted triglyceride in the cell-culture 
medium. In another series of experiments, we treated our hepatoma cells with C14-labelled 
palmitic acid as a labelled source of fatty acids. Palmitic acid was employed for the 
evaluation of the effect of siRNA silencing on fatty acid uptake by the cells, as well as on the 
synthesis and hydrolysis of triglycerides as analyzed in detail in Papers II and III. 
 
3.10 LIPID EXTRACTION 
For the extraction, isolation and quantification of the radio-labelled triglycerides, we used a 
two-phase separation method. A small amount of the cell-lysate or the cell medium was 
added to a mixture of Isopropanol-Hexane (4:1) and incubated for 30 minutes, followed by 
addition of 500 µl of Hexane-Diethyl ether (1:1). After 20 minutes incubation, the bottom 
phase is removed and dried. The sample was dissolved in Heptane and analyzed by thin layer 
chromatography (TLC). The C14-labelled triglycerides were quantified using a scintillation 
counter. 
 
3.11 STATISTICS 
In all the Papers, the analysis and visualization of all the in vitro data was executed by using 
the GraphPad Prism software. Differences in continuous variables between groups were 
tested by Student´s t test.  
In Paper I the association between mRNA expression and the SNPs was tested by multiple 
linear regression and the correlation between mRNA expression and the SNP genotypes was 
examined by ANOVA analysis. 
Level of significance was set to p<0.05 and Bonferroni correction was used to adjust the 
threshold p-values for multiple testing where appropriate. 
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4 RESULTS 
4.1 PAPER I. TM6SF2 IS A REGULATOR OF LIVER FAT METABOLISM 
INFLUENCING TRIGLYCERIDE SECRETION AND HEPATIC LIPID 
DROPLET CONTENT 
 
Identification of TM6SF2 as the putative causal gene responsible for the observed 
relationship with triglyceride concentration in genome-wide association studies  
Genome-wide association studies have shown an association between the 19p12 locus and 
plasma triglyceride concentration, but the identity of the hepatic gene responsible for this 
association was unknown 88–90. We analyzed the hepatic expression of the 19p12 locus genes 
and the lead SNP rs10401969 in human liver biopsies and observed a positive correlation 
between hepatic TM6SF2 mRNA levels and plasma triglyceride concentration. This suggests 
that TM6SF2 is the putative gene in the 19p12 locus involved in triglyceride metabolism. 
 
Subcellular localization of TM6SF2 in human Huh7 hepatoma cells. 
Protein pattern and domain prediction software predicted 7-10 transmembrane domains for 
TM6SF2, indicating that TM6SF2 is a membrane protein. This made us hypothesize that 
TM6SF2 is located in ER. We used GFP-tagged overexpression vector for TM6SF2 in 
combination with FP635-tagged overexpression vector for CALR (an ER marker) to evaluate 
the co-localization of TM6SF2 with the ER (Figure 6).  
 
Figure 6. TM6SF2 is localized in the endoplasmic reticulum. 
  
 
We observed a high co-localization of TM6SF2 with CALR with Rcoloc values of 0.83 ± 
0.04 (mean ± SD). As shown in Figure 2B of Paper I, comparable co-localizations of 
TM6SF2 with Alexa 633-tagged monoclonal antibodies targeting the ER-marker Protein 
Disulfide Isomerase (PDI), with Rcoloc values of 0.78 ± 0.05, or the ER-Golgi intermediate 
compartment protein 2 (ERGIC), with Rcoloc values of 0.80 ± 0.03, were found. In contrast, 
very low co-localization was observed between TM6SF2 and the Golgi complex marker 
Giantin, with Rcoloc values of 0.30 ± 0.08. Overall, this analysis indicates that TM6SF2 is 
primarily localized in the ER. 
Figure 6. Co-localization analysis of TM6SF2 
(green) with CALR (red) in Huh7 hepatoma 
cells. Co-localization was quantified using 
Pearson correlation (Rcoloc) and represents mean 
values of one to three cells evaluated in 4-6 
independent experiments. Scale bar, 10 µm. 
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TM6SF2 influences the secretion of triglyceride-rich lipoproteins and the triglyceride content 
of cellular lipid-droplets.  
We subsequently performed TM6SF2 siRNA silencing experiments and observed that 
TM6SF2 silencing led to decreases in TM6SF2 mRNA and TM6SF2 protein levels in both 
Huh7 and HepG2 hepatoma cells (Figure 3A-D, Paper I).  We also observed a decrease in the 
secretion of TRLs following TM6SF2 siRNA inhibition (Figure 7).  
 
Figure 7. TM6SF2 siRNA inhibition reduces the secretion of triglycerides and APOB by 
human hepatoma cells. 
 
           
 
 
Additionally, TM6SF2 siRNA silencing led to an increase of lipid-droplet content of human 
hepatoma Huh7 cells, as measured both by an in vitro method (Figure 8A) and by confocal 
microscopy (Figures 8B and 8C). Similar effects were observed following TM6SF2 silencing 
of HepG2 cells (Figure 4E-G, Paper I). Moreover, overexpression of FP635 tagged-TM6SF2 
resulted in reduced triglyceride content of Huh7 hepatoma cells as compared to cells not 
overexpressing TM6SF2 (Figure 5, Paper I). Overall, these TM6SF2 siRNA silencing and 
overexpression experiments point to opposing effects of the TM6SF2 concentration on the 
secretion of TRLs and the accumulation of triglycerides in lipid-droplets of the human 
hepatoma cells.     
 
 
 
 
 
 
Figure 7. Effect of TM6SF2 siRNA inhibition on secretion of triglycerides (TG) and apolipoprotein B 
(APOB) by Huh7 and HepG2 hepatoma cells. The values are expressed as percent of control experiments, 
indicated with a dotted line. Values represent mean ± SD of 6-8 independent experiments. Differences were 
determined using Student’s t test. 
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Figure 8. TM6SF2 siRNA silencing reduces cellular triglyceride content and lipid-
droplet area of human hepatoma cells. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Effect of TM6SF2 siRNA inhibition on cellular triglyceride (TG) content (A) and lipid-droplet area 
analyzed by confocal microscopy (B and C) of Huh7 cells. The results are expressed as mean ± SD, n = 6-
8, Scale bar 75 µm. Differences were determined using Student’s t test. 
 
A B C 
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4.2 PAPER II. PNPLA2 INFLUENCES SECRETION OF TRIGLYCERIDE-RICH 
LIPOPROTEINS BY HUMAN HEPATOMA CELLS 
  
PNPLA2, but not PNPLA3 or PNPLA4, influences cellular triglyceride hydrolysis and TLR 
secretion, but not lipid-droplet homeostasis of human hepatoma cells.  
We performed gene-specific siRNA silencing experiments in human hepatoma Huh7 and 
HepG2 cells to evaluate the physiological function of PNPLA2, PNPLA3 and PNPLA4 in 
hepatic triglyceride metabolism. Gene-specific siRNA inhibition led to significant decreases 
of mRNA and protein levels of the respective genes (Figure 1A-C, Paper II). We 
subsequently measured triglyceride hydrolysis activity and observed that PNPLA2 siRNA 
silencing significantly reduced triglyceride hydrolysis while PNPLA3 and PNPLA4 siRNA 
silencing had no effect on triglyceride hydrolysis (Figure 9A).  
Figure 9. PNPLA2 siRNA inhibition reduces triglyceride hydrolysis and decreases TRL 
secretion but does not affect cellular triglyceride accumulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Effects of PNPLA2, PNPLA3, or PNPLA4 siRNA inhibitions 
on triglyceride metabolism of Huh7 and HepG2 hepatoma cells. (A) 
Effects on triglyceride (TG) hydrolysis. (B) Effects on triglyceride 
(TG) and apolipoprotein B (APOB) secretion. (C) Effects on cellular 
TG concentration. The values are expressed as percent of control 
experiments, indicated with a dotted line. The results represent mean ± 
SD of 3-6 independent experiments. Differences were determined 
using Student’s t test. *p<0.05, **p<0.01. 
 
A B 
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Moreover, siRNA silencing of PNPLA2 was associated with reduced triglycerides and APOB 
secretions (Figure 9B). In contrast, no effects of PNPLA3 or PNPLA4 siRNA inhibitions on 
TRL secretion were observed (Figure 9B). Thus, PNPLA2 siRNA inhibition reduced 
triglyceride hydrolysis and TRL secretion in Huh7 and HepG2 cells, while no effects of 
PNPLA3 or PNPLA4 siRNA inhibitions on these functions were observed. 
We subsequently analyzed the effects of PNPLA2, PNPLA3 and PNPLA4 siRNA inhibition 
on cellular triglyceride content. To our surprise, we found that the cellular triglyceride 
concentrations of the Huh7 and HepG2 cells were not affected by either PNPLA2, PNPLA3, 
or PNPLA4 siRNA inhibitions (Figure 9C). Moreover, no effects of PNPLA2 siRNA 
inhibition on lipid-droplet area/cell or lipid-droplet size-distribution was observed in Huh7 
and HepG2 cells analyzed by confocal microscopy (Figure 3, Paper II).   Overall, the gene-
specific siRNA inhibition experiments suggest that PNPLA3 and PNPLA4 do not influence 
hepatic triglyceride metabolism. However, PNPLA2 siRNA inhibition was associated with 
reduced TRL secretion, while no effects on lipid-droplet metabolism were observed.   
 
Atglistatin inhibition of PNPLA2 and PNPLA2 siRNA inhibition have similar effects on 
triglyceride metabolism of human hepatoma cells. 
We used Atglistatin, a pharmacological inhibitor of PNPLA2, to verify the results from the 
PNPLA2 siRNA experiments described above. It was found that Atglistatin treatment, like 
PNPLA2 siRNA inhibition, was associated with reduced triglyceride hydrolysis activity in 
both Huh7 and HepG2 cells (Figure 5A, Paper II). No evidence was found that a combination 
of the two PNPLA2 inhibition methods leads to a greater inhibition of total cellular 
triglyceride-hydrolase activity as compared to PNPLA2 siRNA inhibition alone (Figure 5A, 
Paper II). 
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Figure 10. Comparable effects of PNPLA2 siRNA silencing, Atglistatin treatment or the 
combination of PNPLA2 siRNA silencing and Atglistatin on triglyceride metabolism of 
Huh7 and HepG2 hepatoma cells. 
 
 
 
 
 
 
 
 
 
 
Atglistatin inhibition of PNPLA2 and the combination of Atglistatin and PNPLA2 siRNA 
inhibitions were associated with reduced triglyceride and APOB secretions (Figure 10A). No 
evidence was found that a combination of the two PNPLA2 inhibition methods leads to a 
greater reduction of TRL secretion as compared to PNPLA2 siRNA inhibition alone. 
Additionally, no effects were observed of Atglistatin inhibition or the combination of 
Atglistatin and PNPLA2 siRNA inhibitions on the cellular triglyceride concentrations (Figure 
10B). In short, comparable effects of Atglistatin inhibition and PNPLA2 siRNA inhibition on 
triglyceride metabolism were observed in both hepatoma cell-lines. Moreover, no evidence 
was found for additive effects of the two PNPLA2 inhibition methods on hepatic triglyceride 
metabolism.  
 
PNPLA2 is not associated with lipid-droplets 
The absence of an effect of PNPLA2 inhibition on lipid-droplet metabolism raised the 
question as to the subcellular localization of the PNPLA2 protein. We therefore investigated 
the association of PNPLA2 with lipid-droplets using confocal microscopy, after staining of 
the Huh7 cells with a human monoclonal PNPLA2 antibody and LipidTox Red (Figure 11). 
It was found that PNPLA2 protein is primarily present in the cellular cytoplasm, while no 
enrichment of PNPLA2 was found around the lipid droplets, independently of whether the 
cells were cultured in 10% FBS cell medium or oleate-supplemented cell-medium. Similar 
observations were made when the subcellular localization of PNPLA2 was analyzed in 
HepG2 cells (Figure 6, Paper II).  
B C 
Figure 10. Atglistatin effects on triglyceride metabolism. (A) Effects on triglyceride (TG) and apolipoprotein 
B (APOB) secretion. (B) Effects on cellular TG concentration. The values are expressed as percent of control 
experiments, indicated with a dotted line. The results represent mean ± SD of 3-6 independent experiments. 
Differences were determined using Student’s t test. *p<0.05, **p<0.01, ***p<0.001. 
 
B A 
  25 
Figure 11. PNPLA2 is not associated with lipid-droplets in Huh7 hepatoma cells. 
 
 
 
PNPLA2 shows co-localization with the endoplasmic reticulum 
The observed “cytoplasmic” localization of PNPLA2 (Figure 11) is surprising and may be 
due to its proximity to the cellular compartment responsible for TRL synthesis. We visualized 
the lipid-droplet surface and the ER by employing Perillipin2 (PLIN2) and Protein disulfide 
isomerase (PDI) human monoclonal antibodies, respectively (Figures 7A and 7B, Paper II). It 
was found that PNPLA2 is partially co-localized with PLIN2, with Rcoloc values (mean ± 
SD) of 0.66 ± 0.02 in HepG2 cells and of 0.49 ± 0.07 in Huh7 cells (Figure 7A, Paper II). 
The cytoplasmic distribution pattern of PDI and PNPLA2 showed considerable overlap, with 
Rcoloc values of 0.81 ± 0.05 and 0.61 ± 0.06 for HepG2 and Huh7 cells, respectively (Figure 
12). 
 
Figure 12. Co-localization of PNPLA2 with the endoplasmic reticulum. 
 
  
 
 
Figure 11. Representative confocal microscopy 
images of co-localization analysis of PNPLA2 
(green) with lipid droplets (red) in Huh7 cells 
incubated with FBS-supplemented medium (upper 
lane) or in 0.4 mM oleate-supplemented medium 
(lower lane). 
 
Figure 12. Representative confocal microscopy 
images of PNPLA2 (green) visualizing co-
localization with PDI (red) in HepG2 and Huh7 
cells. Cells were stained with Alexa Fluor 488- 
and Alexa Fluor 594-labelled monoclonal 
antibodies. Colocalization was quantified using 
Pearson correlation (Rcoloc)  
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4.3 PAPER III. THE PNPLA2 CO-ACTIVATOR ABHD5/CGI-58 INFLUENCES 
THE SECRETION OF TRIGLYCERIDE-RICH LIPOPROTEINS IN HUMAN 
HEPATOMA CELLS  
 
ABHD5 siRNA inhibition reduces triglyceride hydrolysis and TLR secretion without affecting 
cellular triglyceride content of Huh7 cells. 
We evaluated the functional role of ABHD5 in hepatic triglyceride metabolism using gene-
specific inhibition of ABHD5 and PNPLA2 in the human hepatoma Huh7 cell-line. ABHD5 
siRNA inhibition led to significant reductions of ABHD5 RNA and ABHD5 protein 
concentrations (Figure 1A and 1B, Paper III). ABHD5 siRNA inhibition reduced triglyceride 
hydrolysis and this effect was comparable to the effect of PNPLA2 siRNA inhibition (Figure 
13). The combined ABHD5 and PNPLA2 siRNA inhibition showed no additive effect on 
triglyceride hydrolysis. Moreover, ABHD5 siRNA inhibition was associated with reductions 
of triglyceride and APOB secretion. Comparable decreases in TRL section were observed 
following PNPLA2 siRNA inhibition and the combined ABHD5 and PNPLA2 siRNA 
inhibition. In contrast, the cellular triglyceride concentrations were not influenced by ABHD5 
siRNA inhibition, PNPLA2 siRNA inhibition or the combined ABHD5 and PNPLA2 siRNA 
inhibition. The results of these inhibition experiments indicate that ABHD5 and PNPLA2 
exhibit comparable effects on triglyceride metabolism in human hepatoma Huh7 cells. 
 
Figure 13. Comparable effects of ABHD5 and PNPLA2 siRNA inhibition on triglyceride 
metabolism of Huh7 cells.  
 
 
 
 
 
 
Figure 13. Effects of ABHD5 and PNPLA2 siRNA inhibition in hepatic triglyceride metabolism. (A) Effects 
on cellular triglyceride (TG) hydrolysis. (B) Effects on TG and apolipoprotein B (APOB) secretion. (C) 
Effects on cellular TG concentration. The values are expressed as percent of control experiments, indicated 
with a dotted line. The results represent mean ± SD of 3-6 independent experiments. Differences were 
determined using Student’s t test. *p<0.05, **p<0.01, ***p<0.001. 
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ABHD5 is not associated with lipid droplets. 
In Study II we reported that PNPLA2 is not associated with cellular lipid-droplets of human 
hepatoma cells. The question was raised as to whether ABHD5 is also absent from lipid-
droplets in Huh7 hepatoma cells. We employed confocal microscopy to evaluate this 
question, following the staining of Huh7 cells with a human monoclonal ABHD5 antibody 
and LipidTox Red. As shown in Figure 14, ABHD5 protein is primarily found in the 
cytoplasm and not around the lipid droplets, a distribution pattern that is similar to the 
subcellular localization of PNPLA2 in hepatoma cells (Figure 3, Paper III). 
 
Figure 14. No evidence for co-localization of ABHD5 with lipid droplets. 
 
 
 
 
ABHD5 is co-localized with PNPLA2 and associated with the endoplasmic reticulum  
The functional analysis and the subcellular localization studies suggested that ABHD5 and 
PNPLA2 collaborate in the regulation of TRL secretion by human hepatocytes. We 
performed co-localization studies to substantiate that the two proteins are present in human 
hepatoma cells in close proximity to one another. ABHD5 and PNPLA2 were stained with 
specific human monoclonal antibodies and the degree of co-localization of the two proteins 
was analyzed using confocal microscopy. As shown in Figure 15, a high degree of co-
localization of ABHD5 with PNPLA2 was observed in human Huh7 hepatoma cells, with 
average Rcoloc values (mean ± SD) of 0.84 ± 0.08. Overall, the co-localization studies 
indicate the close proximity of ABHD5 with PNPLA2. 
 
 
 
 
Figure 14. Representative confocal microscopy images of co-localization 
analysis of PNPLA2 (green) with lipid droplets (red) in Huh7 cells incubated 
with FBS-supplemented medium. 
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Figure 15. Co-localization of ABHD5 and PNPLA2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Representative confocal microscopy image of 
Huh7 hepatoma cells stained with Alexa Fluor 594 -
labelled ABHD5 (red) and Alexa Fluor 488-labelled 
PNPLA2 (green) antibodies. Colocalization was 
quantified using Pearson correlation (Rcoloc) and 
represents mean values of one to three cells evaluated in 
3-4 independent experiments. 
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5 DISCUSSION 
 
In this section of the thesis I will discuss a number of issues and results which were not 
addressed in the Discussion sections of Papers I, II, and III.  
 
5.1 SELECTION OF A MODEL SYSTEM FOR THE STUDY OF HEPATIC 
TRIGLYCERIDE METABOLISM 
The ideal, “golden standard” model for studying triglyceride metabolism in the human liver is 
by using primary human hepatocytes. Freshly isolated human hepatocytes secrete nascent 
TRLs within the VLDL size-range, similar to the secreted lipoproteins found in human serum 
91. However, fresh human liver samples are rarely available and the subsequent isolation of 
hepatocytes is dependent on delicate isolation procedures. Their limited life span, combined 
with phenotypic instability and differentiation within hours after their isolation makes 
primary hepatocytes a challenging study model. Additionally, it is notoriously difficult to 
perform siRNA transfection on primary human hepatocytes because they do not easily absorb 
the lipid complexes required for the transfection, as reviewed in 92. 
Recent advances in maintaining the human liver morphology and specific functions of 
isolated primary human hepatocytes during standard cell culture include the co-culture with 
other cell-types, such as with endothelial cells or 3T3-J2 fibroblasts 93. Additionally, 
formation of 3D-like structures, such as 3D-spheroid cultures, has demonstrated the potential 
to closely mimic human liver function in vitro discovery 94. However, this type of pilot 
modelling systems are characterized by variability between cell-batches originating from 
different donors and lack of established experimental standards 95,96. Addition of chemicals in 
the cell-culture media has been shown to achieve long-term functional maintenance of 
primary hepatocytes, thus opening new horizons for an efficient in vitro model for 
investigation of human hepatic metabolism 97. 
Animal models have been used extensively to study hepatic triglyceride metabolism98. 
Unfortunately, often-used rodent models like mouse and rat show only limited translatability 
as regards human hepatic triglyceride metabolism. An example of the marked difference 
between rodents and humans in hepatic physiology is the secretion of two different isoforms 
of APOB, termed APOB100 and APOB48, by the murine liver, while human hepatocytes 
only secrete TRLs containing APOB-100 44,99. It is likely that different processes regulate the 
synthesis of the two types of TRLs secreted by rodent hepatocytes, but this question has, to 
the best of my knowledge, not been analyzed in any detail. In addition, it is conceivable that 
there are fundamental differences in the synthesis and secretion of APOB-100 containing 
TRLs by human and rodent hepatocytes, but this possibility is rarely considered. 
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Cell-culture systems are often used for functional and mechanistic studies because they offer 
possibilities that are difficult or impossible to achieve using in vivo models. Cell-lines offer 
the advantage of a cheap and flexible study system whose parameters, such as growth and 
culture media, can be easily adjusted. In this Thesis we used Huh7 and HepG2 hepatoma cell-
lines. Unfortunately, there are some differences between these cell-lines and in vivo models; 
Huh7 and HepG2 cells secrete dense, relatively poorly-lipidated lipoproteins in the size - 
range of IDL-LDL, in contrast to the VLDL particles secreted in vivo by the human liver 
100,101. It is generally assumed that this phenomenon is a question of a reduced “thermostat” 
for TRL-secretion in human hepatoma cells, not a matter of a totally different mechanism of 
TRL-secretion. Several other human hepatoma cell-lines are also available, but none of these 
cell-lines have been used and analyzed to the same extent as the Huh7 and HepG2 cell-lines. 
The low rate of secretion of TRLs by Huh7 and HepG2 cells creates challenges for the 
quantification of TRL secretion. We therefore used in all of our studies two different 
parameters to measure TRL secretion, quantifying the secretion of both triglycerides and 
APOB. 
While differences of some metabolic features between Huh7 and HepG2 cells have been 
documented 92,102, we have tried as much as possible to perform duplicate experiments in both 
cell-lines in Papers I and II whereas in Paper III we used only Huh7 cells. Overall comparable 
results were obtained in Papers I and II as regards the analysis of hepatic triglyceride 
metabolism in the two cell-lines. Nevertheless, some minor, quantitative differences between 
the two cell-lines were observed. For example, in Paper I the effect of TM6SF2 siRNA 
silencing on intracellular triglyceride concentrations was slightly stronger in HepG2 cells as 
compared to Huh7 cells, as investigated with both the in vitro triglyceride assay and confocal 
microscopy. In addition, the effects of TM6SF2 siRNA inhibition (Paper I) and PNPLA2 
siRNA inhibition (Paper II) on TRL secretion was greater in Huh7 cells as compared to 
HepG2 cells. It is in this respect noteworthy that the difference in the effects of PNPLA2 
siRNA inhibition on TRL secretion between the two cell-lines was not influenced by the 
addition of oleic acid to the cell-culture medium (Paper II). Finally, in agreement with 
previous reports, we observed that Huh7 cells exhibited generally higher triglyceride and 
APOB secretion rates as compared to HepG2 cells 102,103. In short, the use of the Huh7 and 
HepG2 cell-lines allowed us to perform siRNA inhibition experiments with high efficacy. 
Overall, we observed consistent qualitative effects of the gene-specific inhibitions of 
TM6SF2 and PNPLA2 on hepatic triglyceride metabolism. 
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5.2 THE USE OF OLEIC ACID 
Under fasting conditions, circulating fatty acids are absorbed by the liver and stored in the 
lipid-droplets as triglycerides. Accumulation of excessive amounts of triglycerides results in 
hepatic steatosis, ultimately leading to NAFLD 104,105. The main metabolic aspects associated 
with hepatic steatosis are cellular dysfunction and apoptosis 106,107. Oleic acid is the most 
abundant non-saturated fatty acid present in circulation and has been used in numerous 
studies as an in vitro model of hepatic steatosis. Addition of exogenous unsaturated fatty 
acids, in the form of oleic acid, in the cell-culture media leads to an increase of the number 
and size of lipid-droplets in human Huh7 and HepG2 cell-lines, without induction of 
apoptosis 78,91,108. Incubation with oleic acid also enhances the triglyceride and APOB 
secretion by both cell-lines 100,101,103 and promotes a slight density shift of secreted 
lipoproteins from the LDL size-range to the VLDL size-range 103,109. In contrast, incubation 
of hepatoma cells with saturated fatty acids, such as palmitic acid, has been shown to induce 
cellular toxicity, apoptosis and cell death, accompanied by poor incorporation of the saturated 
fatty acids into lipid droplets 110,111. 
Previous studies have employed oleic acid concentrations between 0.4 mM and 0.8 mM, with 
incubation times ranging from 3 to 24 hours 112–115. The question was raised as to whether the 
relatively high oleate concentrations are required for these studies since they may possibly 
induce cellular toxicity. We therefore compared in Paper II the effect of 0.2 mM oleate-BSA 
conjugate-containing medium to FBS-containing medium in both Huh7 and HepG2 cells. 
Despite the relatively low oleate concentration, we confirmed the oleate effect on cellular 
triglyceride accumulation and TRL secretion. Meanwhile, no cell death was observed as 
measured by total cellular protein (unpublished data). Concentration of 0.2 mM oleic acid 
was sufficient to generate an increase of triglyceride and APOB secretion by more than 100% 
in both cell lines (Figure 4A, Paper II), comparable to the effect of 0.6 mM oleate employed 
in previous studies 103,109. In conclusion, the oleate concentration of 0.2 mM was sufficient to 
stimulate the steps of lipoprotein metabolism that we evaluated in Paper II. 
 
5.3 THE USE OF SIRNA 
One of the experimental approaches used in this Thesis to investigate the function of proteins 
was the loss-of-gene function analysis via RNA interference (RNAi). As described in the 
section Experimental Procedures, RNAi employs either double-stranded siRNA or vector-
based shRNA molecules. Previous studies in our lab have shown a lower silencing efficiency 
of shRNA transfection, combined with cytotoxic effects, as compared to siRNA transfection 
(unpublished data). It is for these reasons that we favor the use of the siRNA technique. 
However, the effect of siRNA is transient; the reduction of the target-protein is brief and 
starts to diminish 48 and 72 hours after transfection 116 . It is for this reason that we 
performed the metabolic analysis within 48 hours after the gene-specific silencing. In 
addition, siRNA inhibition is a knock-down method, not a knock-out procedure. Thus, there 
 32 
always remains some non-degraded mRNA, especially in hard-to-transfect cell-lines, which 
may be enough for the maintenance of basic cellular functions. 
We found no evidence of cellular cytotoxicity or cell death caused by transfection-reagent 
lipofectamine in our experiments, as analyzed by microscopy or measured by the amount of 
total cell protein. In Paper II we consistently observed 75-90% reductions of mRNA levels 
after gene-specific siRNA inhibitions of PNPLA2, PNPLA3 and PNPLA4. In Paper III we 
obtained nearly 90% reductions of ABHD5 mRNA concentration following ABHD5 siRNA 
inhibition. It was reported that HepG2 cells are more difficult to transfect as compared to  
Huh7 cells because they exhibit a high proliferation rate; in every cell-division cycle the 
“lipoplex” (siRNA-containing vesicle) dissociates from the cell-membrane, thus resulting in a 
reduction of the inhibition efficiency 82. Nevertheless, in our experiments we observed no 
consistent difference in the siRNA knock-down efficiency between Huh7 and HepG2 cells. 
Finally, the introduction of siRNA probes can lead to the unintended knockdown of genes not 
being directly targeted. This phenomenon is called “off-target” effect and can lead to 
unexpected results as reviewed in 117. In order to avoid “off-target” effects as much as 
possible, we tested in Papers II and III two different siRNA assays for every different 
knocked-down gene and compared their results (unpublished data). Overall, these consistent 
results indicate that there were limited “off-target” effects after employing transient siRNA 
techniques whereas the inhibition efficiency of the gene-specific silencing was more than 
80%. 
 
5.4 INTERPRETATION OF SUBCELLULAR LOCALIZATION STUDIES 
Subcellular localization analysis provides information regarding the potential mechanistic 
role of a protein in cellular metabolism. Protein visualization and co-localization analysis 
with marker proteins of cellular compartments helps to uncover possible relations and 
interactions between proteins. From an experimental point of view, this approach involves the 
visualization of the target protein and/or organelle with either the (over-)expression of a 
fluorescence-tagged protein-construct or the staining with an antibody. In Paper I, we 
employed both methods to evaluate the role of TM6SF2 in hepatic triglyceride metabolism. 
During the course of the TM6SF2 studies, we became aware of two limitations regarding the 
use of the plasmid overexpression method for metabolic analysis in human hepatoma cells. 
First, we consistently found that only a small number (usually <5%) of all hepatoma cells 
expressed the protein-construct encoded by the plasmid, presumably because of the low 
transfection efficiency of plasmids in the hepatoma cells. Secondly, we noted remarkable 
variation in the overall expression-degree of the protein-constructs in the transfected cells. 
Some cells expressed low levels of protein construct and exhibited a normal cell-morphology 
when examined by confocal microscopy. In contrast, other cells expressed large amounts of 
protein-construct and occasionally showed marked abnormalities of cell-morphology, 
suggestive of cellular decay and death (unpublished data). This phenomenon was previously 
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observed by others and is considered an artifact of the protein-construct transfection method, 
as reviewed in 118.     
Initially, we attributed these cellular effects to artifacts related to the specific features of the 
TM6SF2 plasmid-construct used in these experiments and we focused in our reporting on the 
results of transfected cells with normal cell-morphology. However, in subsequent studies 
involving plasmid constructs for the overexpression of several different proteins (including 
PNPLA2 and ABHD5), we again noted effects of the degree of overexpression on cell-
morphology. In addition, we observed that “low level” of expression led to the localization of 
the GFP-tagged proteins in the cytoplasm whereas we did not observe co-localization of 
ABHD5 protein-construct with lipid-droplets. However, protein expression at “high levels” 
led to the deposition of ABHD5 protein-construct in various subcellular compartments apart 
from the cytoplasm, including lipid-droplets as shown in Figure 16. This is perhaps not 
surprising since lipophilic proteins like ABHD5 and PNPLA2 tend to adhere to membranes. 
In contrast, employing the monoclonal antibody method we did not find any evidence for the 
co-localization of ABHD5 or PNPLA2 with lipid-droplets. We conclude that overexpression 
studies can lead to artifacts that can generate “false” co-localizations of lipophilic proteins to 
the lipid-droplets. 
 
Figure 16. Cell transfection with expression plasmid. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Representative confocal 
microscopy image of transfected Huh7 
cell with GFP-tagged ABHD5 
overexpression vector (green). Lipid 
droplets (red) and nucleus (blue) were 
stained with Lipid-Tox Red and DAPI 
respectively. Scale bar, 10 µm. 
ABHD5 
ABHD5 
Merge Lipid droplets 
LD 
 34 
5.5 ROLE OF TM6SF2 IN HEPATIC TRIGLYCERIDE METABOLISM 
It is generally assumed that variation in TRL secretion is the result of changes in the 
availability of triglycerides for TRL synthesis by the liver 43,44,119. This hypothesis is 
supported, among others, by studies that have shown that increased availability of fatty acids 
to hepatocytes lead to increased cellular triglyceride concentrations and enhanced secretion of 
TRLs, as reviewed in 48. Contrary to this generally accepted hypothesis, we observed in Paper 
I that TM6SF2 siRNA inhibition of human hepatoma cells leads to increased cellular 
triglyceride content and a reduced secretion of TLRs. We noted that these reciprocal changes 
are in agreement with the population genetics analysis of the TM6SF2 locus 75,120, but we did 
not discuss the putative pathophysiological mechanism of this observation.  
Modulation of TM6SF2 expression in mouse model results in similar phenotype compared to 
the phenotype that we report in Paper I 121–123. Smagris et al showed that the opposing effects 
of TM6SF2 on hepatic triglyceride metabolism are due to a role of TM6SF2 in neutral-lipid 
addition during the synthesis of TRLs 123. They proposed that a reduction of TM6SF2 
diminishes the incorporation of triglycerides in TRLs, thereby leading to accumulation of 
triglycerides in hepatic lipid-droplets. This hypothesis is compatible with the observed 
subcellular localization of TM6SF2 in endoplasmic reticulum, as reported in Paper I. 
However, it is worth mentioning two unpublished observations in human hepatoma cells 
which are not compatible with this hypothesis. First, it is well known that hepatoma cells 
exhibit a low secretion rate of relatively triglyceride-poor TRLs 91. This inhibition of TRL 
secretion by itself is not sufficient for the generation of a detectable increase in cellular 
triglyceride concentration. A quantitative analysis of triglyceride secretion by hepatoma cells 
confirmed that the triglycerides required for TRL secretion are not sufficient to explain the 
observed increase in cellular triglyceride concentration after TM6SF2 siRNA inhibition. 
Secondly, by using APOB siRNA inhibition we were able to decrease TRL secretion by 
>90% in the human hepatoma cell-lines. However, no detectable increase in cellular 
triglyceride concentration was observed. It is noteworthy that treatment of patients with 
Familial Hypercholesterolemia with Mipomersen, a second-generation APOB antisense 
oligonucleotide, is associated with only minor, transient increases in liver fat 124,125. Taken 
together, our studies in human hepatoma cells indicate that TM6SF2 exerts an effect on 
cellular triglyceride concentration that is not directly bound to TRL secretion. Of note, 
Ruhanen et al. recently proposed a role of TM6SF2 in altering membrane fatty-acid 
composition, suggesting that alternative mechanisms may account for the impact of TM6SF2 
on TRL secretion and lipid-droplet metabolism 126.                     
             
 
 
  35 
5.6 ROLE OF PNPLA2 IN HEPATIC TRIGLYCERIDE METABOLISM 
In order to better understand the triglyceride metabolism in the human liver, we tried to 
identify the putative triglyceride hydrolase in Paper II by evaluating the role of the three 
highly expressed members of the PNPLA family in human hepatoma cells. Contrary to the 
adipose tissue, the hepatic function of the PNPLA family proteins remains unclear. We show 
that only reduction of the PNPLA2 hepatic expression, and not of PNPLA3 and PNPLA4, is 
associated with reduction of triglyceride hydrolysis and of the TRL secretion in our hepatoma 
model. In contrast, previous in vitro and population studies assigned a role of PNPLA3 in 
hepatic lipid-droplet hydrolysis and VLDL secretion due to its in vitro hydrolase activity and 
due to the phenotype of the I148M polymorphism respectively 127. However, subsequent 
study found that the physiological role for PNPLA3 is mainly restricted to mediate the 
remodeling of triglycerides and phospholipids on lipid-droplets 128. 
We found that PNPLA2 siRNA inhibition resulted in a decrease of the total cellular 
triglyceride hydrolysis by approximately 50%. This suggests, in agreement with previous 
studies that PNPLA2 plays a role in hepatic triglyceride hydrolysis 35,129. However, it was 
puzzling that we did not observe a greater decrease in cellular triglyceride hydrolysis, 
considering the near complete reduction of PNPLA2 RNA concentration and PNPLA2 
protein concentration following PNPLA2 siRNA inhibition.  One possible explanation of the 
phenomenon is that the PNPLA2 protein remaining after PNPLA2 siRNA inhibition is able to 
provide approximately 50% of the cellular triglyceride activity in the hepatoma cells. 
However, we observed a comparable 50% reduction of cellular triglyceride hydrolysis 
following PNPLA2 inhibition by Atglistatin. Moreover, no additive effects of inhibition with 
both PNPLA2 siRNA and Atglistatin were observed. This indicates that a complete inhibition 
of all PNPLA2-dependent triglyceride hydrolysis accounts for approximately 50% of the 
overall cellular triglyceride hydrolase activity in human hepatoma cells. This suggests that the 
remaining 50% of the cellular triglyceride hydrolase activity is provided by alternative, 
currently unknown triglyceride hydrolases, as proposed by others 35,130. 
The subsequently evaluation of the effect of PNPLA2 inhibition on TRL secretion revealed 
that both the secretions of triglyceride and APOB decreased following PNPLA2 siRNA 
inhibition, PNPLA2 inhibition with Atglistatin and the combined inhibition of PNPLA2 with 
PNPLA2 siRNA inhibition and Atglistatin treatment. In contrast, it was reported that 
adenoviral-mediated PNPLA2 knockdown and hepatocyte-specific genetic deletion of 
PNPLA2 did not influence VLDL secretion 131,132  as reviewed in 35. We attribute this 
discrepancy in the secretion of TRLs to species-specific differences in TRL secretion 
between humans and rodents. Again, it was found that PNPLA2 siRNA inhibition, PNPLA2 
inhibition with Atglistatin and the combined inhibition of PNPLA2 with PNPLA2 siRNA 
inhibition and Atglistatin treatment lead to approximately 30% reductions of TRL secretion 
in human hepatoma cells. This indicates that that there are other mechanisms besides 
PNPLA2 that regulate the supply of fatty acids for TRL synthesis 35. 
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Finally, we observed that inhibition of PNPLA2 did not affect the cellular triglyceride 
concentration or influence the size, number or distribution of the lipid droplets as examined 
by confocal microscope, despite a 50% reduction of the cellular triglyceride hydrolysis 
activity of the hepatoma cells. In agreement with this observation, we found that PNPLA2 
was not localized around lipid-droplets, suggesting that the triglycerides present in lipid-
droplets visualized by confocal microscopy are not the substrate for PNPLA2-mediated 
triglyceride hydrolysis. In contrast, we found that PNPLA2 was present in the cytoplasm of 
the hepatoma cells. Moreover, we observed co-localization of PNPLA2 with the ER and 
PLIN2, indicating that PNPLA2 is associated with small lipid-droplets near the ER. It is in 
this respect important to mention the presence  of different lipid-droplet subpopulations in 
hepatoma cells: large lipid-droplets (designated L-LDs) that are visible by confocal 
microscopy, and small lipid-droplets (designated S-LD) that are only visible by electron 
microscopy 133. It is likely that these different lipid-droplet subpopulation have different 
metabolic functions, as discussed below 28. 
 
5.7 ROLE OF ABHD5 IN HEPATIC TRIGLYCERIDE METABOLISM 
In Paper III we evaluated the functional role of ABHD5 and its relationship with PNPLA2 
regarding cellular triglyceride hydrolysis, TRL secretion, lipid-droplet metabolism and 
subcellular localization in human hepatoma Huh7 cells. It was found thatABHD5 siRNA 
inhibition is associated with reduced cellular triglyceride hydrolysis in Huh7 hepatoma cells. 
A comparable, partial reduction of cellular triglyceride hydrolysis activity after ABHD5 
siRNA was previously observed in liver-specific knock-down of ABHD5 in mice 37. In 
agreement with previous studies in murine models 37,39,115,  it was found that ABHD5 siRNA 
inhibition decreased TRL secretion in Huh7 cells by approximately  50%. However, no 
effects of ABHD5 siRNA inhibition on cellular triglyceride concentration or on the 
concentration and size of the lipid-droplets was observed in confocal microscopy studies. 
Finally, it was found in subcellular localization studies that ABHD5 was not associated with 
lipid-droplets, but was present in the cytoplasm of the Huh7 hepatoma cells, near the ER. 
Overall, our analysis of the role of ABHD5 in triglyceride metabolism in Huh7 cells shows 
remarkable similarities with the previous analysis (Paper II) of the role of PNPLA2 in 
triglyceride metabolism of human hepatoma cells. Indeed, a head-to-head comparison of the 
effects of ABHD5 and PNPLA2 siRNA inhibitions on triglyceride metabolism in Huh7 cells 
found no evidence for distinct differences between the two interventions. Moreover, no 
additive effects were observed when the ABHD5 and PNPLA2 siRNA inhibitions were 
combined and compared with either ABHD5 siRNA or PNPLA2 siRNA inhibitions. These 
observations suggest that both ABHD5 and PNPLA2 are involved in the same metabolic 
network related to cellular triglyceride metabolism in human hepatoma cells. However, it 
must be stressed that in this study we only analyzed the effects of ABHD5 and PNPLA2 
siRNA inhibitions on specific functions of hepatic triglyceride metabolism, and it remains 
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therefore possible that ABHD5 exhibits a PNPLA2-independent role in lipid homeostasis, as 
proposed by Lord et al 134. 
The subcellular localization studies reinforced our conclusion that ABHD5 and PNPLA2 act 
in the same metabolic network in Huh7 cells. We found a substantial co-localization of 
ABHD5 and PNPLA2 in Huh7 cells near the ER. Of note, in agreement with our previous 
analysis of PNPLA2 in Huh7 cells (Paper II), we found no evidence for a localization of 
ABHD5 around lipid-droplets. Further studies are in progress to define in more detail the 
subcellular localization of these proteins in Huh7 hepatoma cells. Overall, our studies support 
the notion that ABHD5 acts as a co-activator of PNPLA2 in Huh7 hepatoma cells, in a 
similar manner as proposed for the interaction of ABHD5 and PNPLA2 in human adipose 
tissue 36. 
 
5.8 POTENTIAL ROLE OF SMALL LIPID-DROPLETS IN THE REGULATION OF 
TRL SECRETION 
Papers II and III of this Thesis provide evidence that cellular triglyceride hydrolysis 
constitutes an important mechanism for the regulation of TRL secretion by human hepatoma 
cells. It was found that both PNPLA2 and ABHD5 serve important roles in this process, 
presumably acting as the predominant triglyceride-hydrolase enzyme (PNPLA2) and as 
activator of triglyceride-hydrolase activity (ABHD5). At the same time, confocal microscopy 
studies provided no evidence for the co-localization of either PNPLA2 or ABHD5 with large 
lipid-droplets and no evidence was found for the effects of PNPLA2 and/or ABHD5 siRNA 
inhibitions on cellular lipid-droplet size and lipid-droplet number. This raises the critical 
question as to the subcellular localization of the triglycerides that are hydrolyzed by the 
combined action of PNPLA2 and ABHD5 activity in the hepatoma cells. This question, in 
turn, has important consequences for the nature of the metabolic pathways governing fatty 
acid metabolism of hepatocytes.   
Panel A of Figure 17 presents a schematic overview of the current working-model regarding 
the fate of fatty acids in hepatocytes. As shown in this Figure, some fatty acids are generated 
by the hepatocyte itself, a process termed de novo fatty acid synthesis. However, an important 
source of intracellular fatty acids is derived from the uptake of fatty acids present in the 
circulation in association with plasma albumin. A third source of fatty acids is the lysosomal 
hydrolysis of triglycerides present in the lipoprotein remnants removed from the circulation 
by the liver. These fatty acids are used in hepatocytes for three main purposes: firstly, for 
beta-oxidation of the fatty acids in the mitochondria; secondly, for storage of the fatty acids in 
the form of triglycerides in lipid-droplets; and thirdly, for incorporation of the fatty acids in 
the triglycerides of TRLs secreted by the hepatocytes. The fatty acids stored in the 
triglycerides of the lipid-droplets, in turn, can be mobilized again and can be used for beta-
oxidation or the synthesis of TRLs. All of these processes require considerable intracellular 
movement of fatty acids between different subcellular compartments of the hepatocyte. These 
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fatty acid transport processes are facilitated by a variety of transport proteins, receptors and 
other auxiliary proteins. Nevertheless, the toxic nature of fatty acids will drive the hepatocyte 
to convert fatty acids into temporary storage in the form of triglycerides, again requiring 
different proteins for lipid-droplet formation and enzymes for triglyceride synthesis and 
hydrolysis. In short, the intracellular movement of fatty acids is a complex system that 
requires a large number of cellular proteins that perform and regulate the demand and supply 
of fatty acids for various metabolic function in hepatocytes.  
The Farese-Walther laboratory recently identified two types of intra-cellular lipid-droplets 
generated by the ER 20: 1) large-sized lipid-droplets (L-LDs, also designated as eLDs), 
equipped with the enzymatic machinery to develop into the mature lipid-droplets observed by 
confocal microscopy, and 2) small-sized lipid-droplets (S-LDs, also designated as iLDs) that 
lack the ability to develop into mature lipid-droplets and are therefore not visible by confocal 
microscopy. The function of the S-LDs is as yet unknown. However, it is tempting to 
speculate that the triglycerides present in the S-LDs is the substrate for PNPLA2 mediated 
triglyceride hydrolysis. It is possible that PNPLA2 is attached to the S-LD and that activation 
of triglyceride hydrolase activity by ABHD5 is required to generate the fatty acids necessary 
for TRL synthesis. An alternative hypothesis is that PNPLA2 is associated with the TRL-
synthesis complex and interacts with the S-LD in a similar fashion as Lipoprotein Lipase with 
circulating TRLs. This possibility is supported by the strong co-localization of PNPLA2 with 
Protein disulfide isomerase, a well-known ER-marker that is part of the MTTP complex. 
Clearly, more studies are required to substantiate the hypothesis that S-LDs are an important 
source of triglyceride-derived fatty acids for TRL-synthesis. 
The immediate follow-up question is the origin of the S-LDs used for TRL-synthesis. It was 
shown by the Farese-Walther laboratory that the S-LDs and L-LDs are generated using 
essentially the same synthetic machinery, but this does not exclude the possibility that the S-
LDs and L-LDs are synthesized at different locations in the ER. Moreover, it is conceivable 
that the ER-site for TRL synthesis may be quite far removed from the ER-sites for the de 
novo synthesis of S-LDs. Indeed, it is possible that S-LDs are generated at different sites of 
the ER, for example in conjunction with the uptake of fatty acids in the vicinity of the cell-
membrane, the liberation of fatty acids by lysosomal degradation of remnant lipoproteins, or 
the de novo synthesis of fatty acids, and can act as a convenient subcellular ‘shuttle’ of 
triglycerides from various sites in the ER to the TRL-synthesis complex. It is possible that 
this form of intra-cellular fatty acid transport via S-LDs exists in parallel with the transport of 
fatty acids by fatty-acid binding protein.   
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Figure 17B provides an update of our current working-model describing the fate of fatty 
acids in hepatocytes. In this revision of Figure 17A we removed the arrow pointing at the 
transfer of fatty acids from L-LD to the ER-site for TRL synthesis. Moreover, we reduced the 
significance of direct transfer of fatty acids to the ER-site for TRL synthesis. Instead, we 
introduced in Figure 17B the concept of triglyceride transport via S-LDs to the ER-site for 
TRL synthesis.       
Figure 17. Schematic figure representing the model of function of PNPLA2 and ABHD5 
in triglyceride hydrolysis and secretion.                                          
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Figure 17. Representative model of triglyceride metabolism in hepatocytes before (A) and after 
(B) the publication of the present Thesis. The intracellular transport of the fatty acids (FA) is 
symbolized by the black and red arrows while the secretion of the lipidated apolipoprotein B 
molecule (APOB100) is represented by the green arrow. 
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6 CONCLUSIONS 
 
The main findings of this thesis work can be summarized as the following: 
 
1. TM6SF2 is a regulator of liver fat metabolism with opposing effects on the secretion 
of TRLs and hepatic lipid droplet content. 
2. PNPLA2 influences TRL secretion but is not involved in lipid-droplet homeostasis in 
human hepatoma cells, a physiological role that is quite distinct from the metabolic 
function of PNPLA2 in non-hepatic tissues. 
3. ABHD5 acts as a co-activator of PNPLA2 in Huh7 cells and provide further evidence 
for a role of ABHD5-PNPLA2 mediated triglyceride hydrolysis in the regulation of 
TRL secretion. 
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